Grandeur Peak Global Advisors LLC purchased a new position in shares of Neogen Corporation (NASDAQ:NEOG – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 148,256 shares of the company’s stock, valued at approximately $1,333,000. Grandeur Peak Global Advisors LLC owned about 0.07% of Neogen as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. Sei Investments Co. lifted its position in shares of Neogen by 69.1% during the 1st quarter. Sei Investments Co. now owns 230,403 shares of the company’s stock valued at $2,141,000 after buying an additional 94,148 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in Neogen in the 1st quarter worth about $2,980,000. Roubaix Capital LLC bought a new stake in Neogen in the 1st quarter valued at about $4,630,000. Granahan Investment Management LLC bought a new stake in Neogen in the 1st quarter valued at about $2,323,000. Finally, Deutsche Bank AG purchased a new stake in Neogen during the second quarter valued at about $3,382,000. Institutional investors own 96.73% of the company’s stock.
Neogen News Summary
Here are the key news stories impacting Neogen this week:
- Positive Sentiment: Piper Sandler upgraded Neogen on new management, suggesting analysts see potential for improved execution and a stronger outlook under the company’s leadership changes. Neogen upgraded at Piper Sandler on new management
- Positive Sentiment: Zacks Research raised several Neogen EPS forecasts: FY2027 estimates increased to $0.25 from $0.21, FY2028 to $0.29 from $0.28, and FY2029 was projected at $0.32. Quarterly estimates for Q2 and Q3 FY2027, Q4 FY2027 and Q3–Q4 FY2028 were also raised, signaling expectations for gradual earnings improvement. These forecasts are broadly in line with or above the current-year consensus of $0.25 EPS.
- Neutral Sentiment: Signal Proxy Intelligence recommended shareholders support all five proposals at Neogen’s annual meeting. The endorsement may reduce governance uncertainty, but it is unlikely to materially change near-term earnings or valuation. Signal Proxy Intelligence Recommends Full Support for All Five Items at Neogen Corporation Annual Meeting
- Neutral Sentiment: A Zacks comparison of Perrigo and Neogen framed the stocks as competing medical-products value investments. The article does not represent a specific change to Neogen’s rating or outlook. PRGO or NEOG: Which Is the Better Value Stock Right Now?
- Negative Sentiment: Zacks lowered its Q1 FY2028 EPS forecast to $0.05 from $0.06, partially offsetting the broader upward revisions. The change suggests some unevenness in the pace of Neogen’s expected earnings recovery.
Neogen Stock Up 0.3%
Neogen (NASDAQ:NEOG – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The firm had revenue of $225.30 million for the quarter, compared to analysts’ expectations of $212.35 million. During the same period in the prior year, the business posted ($2.82) earnings per share. The company’s revenue was down .1% on a year-over-year basis. Research analysts anticipate that Neogen Corporation will post 0.27 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on NEOG. Weiss Ratings upgraded shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Piper Sandler upgraded shares of Neogen from a “neutral” rating to an “overweight” rating and upped their price target for the company from $13.00 to $14.00 in a research note on Wednesday. Finally, Wall Street Zen raised shares of Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $12.00.
Get Our Latest Analysis on Neogen
About Neogen
Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.
In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.
Recommended Stories
- Five stocks we like better than Neogen
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.